Rothschild Investment LLC Buys Shares of 9,885 Icon Plc $ICLR

Rothschild Investment LLC bought a new position in shares of Icon Plc (NASDAQ:ICLR) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 9,885 shares of the medical research company’s stock, valued at approximately $1,730,000.

A number of other large investors have also made changes to their positions in ICLR. Private Trust Co. NA lifted its stake in shares of Icon by 200.0% in the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 94 shares during the period. Ameritas Advisory Services LLC purchased a new position in Icon in the second quarter valued at about $48,000. LRI Investments LLC acquired a new stake in shares of Icon during the 2nd quarter valued at approximately $49,000. Blue Trust Inc. boosted its stake in shares of Icon by 44.0% during the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after acquiring an additional 120 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its stake in shares of Icon by 153.4% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after acquiring an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

ICLR has been the subject of several research analyst reports. UBS Group set a $220.00 price objective on Icon in a research note on Friday, October 24th. BMO Capital Markets started coverage on Icon in a research report on Thursday, November 13th. They issued a “market perform” rating and a $175.00 price target for the company. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Robert W. Baird set a $220.00 price objective on shares of Icon in a research note on Friday, October 24th. Finally, Cowen restated a “hold” rating on shares of Icon in a report on Friday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $204.56.

Icon Trading Down 7.2%

Shares of ICLR stock opened at $188.22 on Friday. The company has a market capitalization of $15.20 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 4.24 and a beta of 1.26. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average price of $177.07 and a 200 day moving average price of $172.51. Icon Plc has a twelve month low of $125.10 and a twelve month high of $220.93.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.